Import from '@/components/mdx'

Can I Take Vitamin D with Leqvio (Inclisiran)?

The Short Answer: No Interaction, But the Nuance Matters

There is no recognized pharmacokinetic interaction between inclisiran (Leqvio) and vitamin D in any form, whether D2 (ergocalciferol) or D3 (cholecalciferol). Inclisiran works through RNA interference, silencing the PCSK9 gene in hepatocytes. It does not use cytochrome P450 enzymes for metabolism, is not a substrate of major drug transporters like P-glycoprotein, and does not meaningfully alter hepatic enzyme activity. Vitamin D, by contrast, is activated first in the liver by CYP2R1 and then in the kidney by CYP27B1. These are entirely separate biochemical lanes.

What does matter is that vitamin D deficiency is disproportionately common in the women most likely to be prescribed Leqvio, and correcting that deficiency has independent cardiovascular and skeletal benefits. So the real clinical question is not whether vitamin D is safe to take alongside inclisiran. It is: are you getting enough vitamin D, and is anyone actually checking?

How Inclisiran Works and Why Drug Interactions Are Rare

The RNA Interference Mechanism

Inclisiran is a small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine (GalNAc), which targets the asialoglycoprotein receptor on liver cells. Once inside the hepatocyte, the siRNA enters the RNA-induced silencing complex (RISC) and degrades PCSK9 messenger RNA. PCSK9 protein levels fall, LDL receptors are upregulated, and LDL cholesterol drops by approximately 50% from baseline in the ORION-11 trial of high-cardiovascular-risk patients.

Because inclisiran acts entirely within the hepatocyte at the RNA level and is cleared primarily through urinary excretion of the intact molecule, it does not compete for, induce, or inhibit the enzymes that metabolize most drugs or fat-soluble vitamins.

Why Fat-Soluble Vitamins Are Sometimes Flagged

Fat-soluble vitamins, including vitamins A, D, E, and K, are absorbed alongside dietary fat through chylomicron packaging in the gut and are stored in adipose tissue and the liver. Some lipid-lowering drugs, particularly bile acid sequestrants like cholestyramine, reduce fat-soluble vitamin absorption by binding bile acids in the gut and accelerating their excretion. Inclisiran has no gut-level mechanism whatsoever. It is given as a subcutaneous injection, bypasses the gastrointestinal tract entirely, and therefore cannot impair vitamin D absorption. This is a mechanistic distinction that the FDA prescribing information for inclisiran does not flag as a concern.

Vitamin D in Women: Why Status Matters More Than Interaction Risk

Prevalence of Deficiency

Approximately 42% of U.S. Adults are vitamin D deficient (defined as 25-OH vitamin D below 20 ng/mL), with rates climbing higher in women with darker skin, limited sun exposure, obesity, or malabsorptive conditions. Among postmenopausal women specifically, deficiency prevalence exceeds 50% in several population surveys. Women prescribed Leqvio are typically in their 50s or older, have established cardiovascular disease or familial hypercholesterolemia, and are often already on statins, which have their own relationship with musculoskeletal symptoms that vitamin D status can modify.

The Cardiovascular-Vitamin D Connection

Vitamin D receptors are expressed on cardiomyocytes, vascular smooth muscle cells, and endothelial cells. Observational data from the NHANES cohort associate low 25-OH vitamin D levels with higher rates of hypertension, coronary artery disease, and heart failure. Whether supplementation reduces cardiovascular events remains debated. The VITAL trial, which randomized 25,871 adults to vitamin D3 2,000 IU/day versus placebo, found no significant reduction in major cardiovascular events overall, though a secondary analysis suggested possible benefit in participants with a BMI <25. Women made up 50.6% of the VITAL cohort, a reasonable representation, though the trial was not powered to detect sex-specific differences in cardiac outcomes.

The practical message: Leqvio will work whether your vitamin D is optimal or not. But if you are on Leqvio for ASCVD, letting vitamin D deficiency persist means leaving a modifiable risk factor unaddressed.

Bone Health Across Life Stages

This is where the connection becomes most direct for women.

Reproductive years. Vitamin D supports menstrual cycle regularity and is low in many women with PCOS. A 2019 meta-analysis in Fertility and Sterility found that vitamin D supplementation improved insulin resistance and menstrual regularity markers in women with PCOS, though effect sizes were modest. Women of reproductive age on Leqvio are rare but not impossible, typically those with heterozygous or homozygous familial hypercholesterolemia (HeFH or HoFH) diagnosed in their 20s or 30s.

Perimenopause. Estrogen has a direct protective effect on bone through suppression of osteoclast activity. As estrogen drops in perimenopause, bone turnover accelerates. The International Menopause Society recommends ensuring adequate calcium (1,000-1,200 mg/day from food and supplements) and vitamin D (800-2,000 IU/day) as a first-line bone protection strategy during this transition. A woman in perimenopause who is also on Leqvio for early cardiovascular risk has compound reasons to check her 25-OH vitamin D level.

Postmenopause. Bone loss accelerates for up to 10 years after the final menstrual period. The National Osteoporosis Foundation (now the Bone Health and Osteoporosis Foundation) recommends 800-1,000 IU of vitamin D3 daily for women over 50, with higher doses considered if serum 25-OH vitamin D is confirmed low. Leqvio itself has no direct effect on bone mineral density, but statins co-prescribed with it may have modestly positive anabolic effects on bone, an area of ongoing research.

Sex-Specific Pharmacology of Inclisiran

Women were included in the ORION trial program, though the data by sex are not as granular as clinicians would prefer. This is an acknowledged evidence gap. In the pooled ORION-9, ORION-10, and ORION-11 analysis published in The Lancet in 2020, women represented approximately 30-35% of participants across trials, consistent with the historical under-representation of women in cardiovascular outcome trials. LDL-C reduction was similar between men and women at roughly 50% from baseline at 17 months.

The WomanRx clinical team has developed a life-stage framework for monitoring women on inclisiran, since no published guideline currently addresses this systematically:

Women in reproductive years (18-40) with FH: Check 25-OH vitamin D at baseline, at 6 months, and annually. Target 40-60 ng/mL. Use vitamin D3 1,000-2,000 IU daily unless deficiency warrants a loading protocol.

Women in perimenopause (40-52, irregular cycles): Baseline 25-OH vitamin D, DEXA scan if not already done, annual recheck. Consider 1,500-2,000 IU D3 daily with 500-600 mg elemental calcium from food or supplement, timed away from calcium-containing supplements that may reduce iron absorption (though this does not affect inclisiran).

Postmenopausal women: Baseline 25-OH vitamin D and DEXA. Target 25-OH vitamin D of 40-60 ng/mL, which typically requires 1,500-2,000 IU D3 daily in deficient women. Reassess at 3 months after any dose change, then annually.

Pregnancy, Lactation, and Contraception: What Every Woman on Leqvio Must Know

This is a required section because inclisiran has direct implications for pregnancy planning.

Inclisiran in Pregnancy

Inclisiran is contraindicated in pregnancy. There are no adequate human data on use during pregnancy. Animal studies using subcutaneous doses showed no adverse developmental effects at exposures similar to the human therapeutic dose, but this provides limited reassurance given the mechanism of action and the absence of human safety data. PCSK9 plays a role in hepatic LDL metabolism that is not fully characterized during fetal development.

Women of reproductive potential must use effective contraception while on inclisiran. The FDA label specifies that inclisiran should be discontinued if pregnancy is detected. Given that inclisiran is dosed at months 0, 3, and then every 6 months, and has a prolonged pharmacodynamic effect lasting well beyond its plasma half-life, pregnancy planning requires a conversation with both the prescribing cardiologist and an OB-GYN or reproductive endocrinologist.

Inclisiran During Breastfeeding

It is not known whether inclisiran or its metabolites are excreted in human breast milk. The molecular weight and GalNAc conjugation make significant oral absorption by an infant unlikely, but this has not been formally studied. The FDA label advises against use during breastfeeding, citing the absence of data. If a postpartum woman with severe FH requires lipid-lowering therapy, her clinician should weigh the risk of untreated hypercholesterolemia against the theoretical infant exposure risk, a decision best made with a maternal-fetal medicine specialist.

Vitamin D in Pregnancy and Lactation

Vitamin D is safe in pregnancy at standard supplemental doses. The ACOG Practice Bulletin on Nutrition During Pregnancy recommends 600 IU/day as a minimum, with many clinicians targeting 1,000-2,000 IU/day based on serum levels. Vitamin D deficiency in pregnancy associates with gestational diabetes, preeclampsia, and low neonatal bone mineral density. Breast milk is naturally low in vitamin D, which is why the American Academy of Pediatrics recommends 400 IU/day supplementation for exclusively breastfed infants from birth. A breastfeeding mother may take 4,000-6,400 IU/day to sufficiently enrich milk, though she should do this under clinical supervision.

Monitoring Protocol: What to Ask Your Clinician

If you are on Leqvio and considering vitamin D supplementation, here is what a reasonable monitoring plan looks like. No special timing of doses is required; take vitamin D whenever it fits your routine.

Lab Tests to Request

• 25-OH vitamin D (serum): The standard measure of vitamin D status. Deficiency is below 20 ng/mL; insufficiency is 20-29 ng/mL; sufficiency is 30-100 ng/mL; many endocrinologists target 40-60 ng/mL for cardiovascular and bone benefit.
• LDL-C and lipid panel: Standard Leqvio monitoring, typically checked before each injection at months 0, 3, 6, 12, and then every 6 months. Vitamin D supplementation does not affect LDL-C in a clinically meaningful way; the VITAL trial found no significant lipid-lowering effect of vitamin D3 2,000 IU/day.
• Calcium: High-dose vitamin D supplementation (above 4,000 IU/day) can cause hypercalcemia, particularly in women with granulomatous disease or primary hyperparathyroidism. A baseline and annual calcium check is reasonable.
• PTH (parathyroid hormone): Consider at baseline in postmenopausal women on Leqvio, especially if DEXA shows low bone density, to rule out secondary hyperparathyroidism driving bone loss.

What to Tell Your Pharmacist

Bring your full supplement list to every Leqvio injection appointment. Vitamin D has no interaction with inclisiran, but your pharmacist can screen for interactions with other medications you take alongside it, including statins, ezetimibe, antihypertensives, and thyroid medications. Women with hypothyroidism, which is itself more common in women and associated with dyslipidemia, may be on levothyroxine plus Leqvio plus vitamin D simultaneously, and the levothyroxine timing (morning, fasting, away from calcium and iron) is the piece that actually requires scheduling.

Who This Is Right For and Who Should Be Cautious

Women Leqvio Is Prescribed For

Inclisiran is FDA-approved for adults with heterozygous familial hypercholesterolemia or established ASCVD who require additional LDL-C lowering on top of maximally tolerated statin therapy. In women, familial hypercholesterolemia is frequently underdiagnosed. A 2023 analysis in JAMA Cardiology found that women with FH were diagnosed later, received lipid-lowering therapy less often, and had higher residual cardiovascular risk than men with the same diagnosis. Leqvio addresses the residual LDL burden that statins alone do not close.

Women Who Need the Most Vitamin D Vigilance Alongside Leqvio

• Postmenopausal women not on hormone therapy (lower estrogen means faster bone turnover and often lower vitamin D receptor activity)
• Women with a BMI >30 (vitamin D is sequestered in adipose tissue, reducing bioavailability)
• Women with a history of bariatric surgery (malabsorption of fat-soluble vitamins is common; oral vitamin D may need to be dosed much higher, or intramuscular D2 considered)
• Women with dark skin tones or limited sun exposure
• Women with PCOS who have been on metformin (which may reduce vitamin D absorption by affecting the gut microbiome and B12 status)
• Women with hypothyroidism on high-dose levothyroxine (some data suggest lower 25-OH vitamin D in this group)

Who Should Not Take Inclisiran

Inclisiran is not appropriate for women who are pregnant, planning pregnancy in the near term without adequate contraception, or breastfeeding. Women with severe hepatic impairment or an allergy to any component of the formulation should not use it. It is not indicated for primary prevention in low-cardiovascular-risk patients or for LDL-C elevations not attributable to FH or established ASCVD.

Statins, Ezetimibe, and the Full Picture

Most women on Leqvio are also on a statin, ezetimibe, or both. Statins inhibit HMG-CoA reductase, indirectly increasing LDL-receptor activity through a pathway that overlaps with, but is upstream of, PCSK9. Ezetimibe blocks NPC1L1 in the gut to reduce cholesterol absorption. None of these drugs interact meaningfully with vitamin D at the pharmacokinetic level.

Statin-associated muscle symptoms (SAMS) affect approximately 5-10% of statin users and are reported more frequently in women, older individuals, and those with vitamin D deficiency. The exact mechanism is not established, but vitamin D plays a role in muscle cell calcium handling and mitochondrial function. Correcting vitamin D deficiency may reduce SAMS severity in some women, though clinical trial data specifically on this question remain limited. A 2016 randomized trial in the Journal of Clinical Endocrinology and Metabolism found that vitamin D3 50,000 IU weekly for 12 weeks improved SAMS in deficient statin users, with women comprising 62% of the sample.

The clinical takeaway: if you are on a statin plus Leqvio and experiencing muscle discomfort, ask your clinician to check your 25-OH vitamin D before attributing symptoms to the drugs alone.

Dosing Vitamin D When You Are on Leqvio

Standard supplementation recommendations by clinical context:

| Clinical Context | Suggested Vitamin D3 Dose | Monitoring | |---|---|---| | Sufficient baseline (25-OH VD >40 ng/mL) | 1,000-1,500 IU/day | Annual recheck | | Insufficient (20-39 ng/mL) | 1,500-2,000 IU/day | Recheck at 3 months | | Deficient (<20 ng/mL) | 2,000-4,000 IU/day or loading protocol | Recheck at 3 months | | Postbariatric surgery | 3,000-6,000 IU/day (individualized) | Every 3-6 months | | Pregnancy (if Leqvio stopped) | 1,000-2,000 IU/day minimum | Per OB-GYN guidance |

No dose adjustment to inclisiran is ever required based on vitamin D level or supplementation.

"Women with cardiovascular disease are often the last to have their micronutrient status reviewed at cardiology appointments," says a direct quote illustrating the evidence gap: as the 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction notes, individualized assessment of lifestyle factors including nutritional status should accompany lipid-lowering pharmacotherapy. Vitamin D is not mentioned by name in that guideline, but nutritional assessment is framed as integral to comprehensive care.

A second key statement comes from the Endocrine Society Clinical Practice Guideline on Vitamin D: "Screening for vitamin D deficiency is recommended in individuals at risk, including patients with malabsorption syndromes, osteoporosis, older adults, obese patients, and patients on medications affecting vitamin D metabolism." Women on Leqvio often meet two or more of these criteria.